|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cirrhosis and autoimmune liver disease:Current understanding显示文摘Primary biliary cirrhosis(PBC),primary sclerosing cholangitis(PSC) and autoimmune hepatitis(AIH) constitute the classic autoimmune liver diseases(AILDs).While AIH target the hepatocytes,in PBC and PSC the targets of the autoimmune attack are the biliary epithelial cells.Persistent liver injury,associated with chronic AILD,leads to un-resolving inflammation,cell proliferation and the deposition of extracellular matrix proteins by hepatic stellate cells and portal myofibroblasts.Liver cirrhosis,and the resultant loss of normal liver function,inevitably ensues.Patients with cirrhosis have higher risks or morbidity and mortality,and that in the decompensated phase,complications of portal hypertension and/or liver dysfunction lead to rapid deterioration.Accurate diagnosis and monitoring of cirrhosis is,therefore of upmost importance.Liver biopsy is currently the gold standard technique,but highly promising non-invasive methodology is under development.Liver transplantation(LT) is an effective therapeutic option for the management of endstage liver disease secondary to AIH,PBC and PSC.LT is indicated for AILD patients who have progressed to end-stage chronic liver disease or developed intractable symptoms or hepatic malignancy;in addition,LT may also be indicated for patients presenting with acute liver disease due to AIH who do not respond to steroids. | Rodrigo Liberal Charlotte R Grant | 2016 | World Journal of Hepatology2016，8，28： | 10 |
| 2 | Management of autoimmune hepatitis:Focus on pharmacologic treatments beyond corticosteroids显示文摘In autoimmune hepatitis, patients who are intolerant or with toxicity experience, non-responders, relapsers or refractory are challenging. Non-standard drugs are being tried to preemptively avoid corticosteroid-related side effects. Prognosis and quality of life of life rely on treatment optimization. Recently, emergence of powerful immunosuppressive agents, mainly from liver transplantation, challenged the supremacy of the corticosteroid regime and promise greater immunosuppression than conventional medications, offer site-specific actions and satisfactory patient tolerance. Successes in experimental models of related diseases have primed these molecular interventions. We performed a literature review on alternative treatments. Azatioprine intolerance is the principal indication for mycophenolate use butit can be used as a front-line therapy. Cyclosporine A and tacrolimus have been tested for non-responders or relapsers. Rituximab may be used as salvage therapy. Anti-tumor necrosis factor-alpha agents may be used for incomplete responses or non-responders. Methotrexate is possibly an alternative for induction of remission and maintenance in refractory patients. Cyclophosphamide has been included in the induction regimen with corticosteroids. Ursodeoxycholic acid action is mainly immunomodulatory. Non-standard treatments are coming slowly to the attention, but its use should be cautious performed by experienced centers. | Marta Casal Moura Rodrigo Liberal Hélder Cardoso Ana Maria Horta e Vale Guilherme Macedo | 2014 | World Journal of Hepatology2014，6，6： | 2 |
| 3 | Autoimmune Hepatitis After Liver Transplantation显示文摘 | Rodrigo Liberal Maria Serena Longhi Charlotte R. Grant Giorgina Mieli–Vergani Diego Vergani | 2012 | Clinical Gastroenterology and Hepatology2012，，4： | 2 |
| 4 | Dysfunctional CD39POS regulatory T cells and aberrant control of T‐helper type 17 cells in autoimmune hepatitis显示文摘 | Charlotte R. Grant Rodrigo Liberal Beth S. Holder John Cardone Yun Ma Simon C. Robson Giorgina Mieli‐Vergani Diego Vergani Maria Serena Longhi | 2014 | Hepatology2014，，： | 1 |
| 5 | Diagnostic criteria of autoimmune hepatitis显示文摘 | Rodrigo Liberal Charlotte R. Grant Maria Serena Longhi Giorgina Mieli-Vergani Diego Vergani | 2014 | Autoimmunity Reviews2014，，4： | 1 |
| 6 | Inhibition of Interleukin-17 Promotes Differentiation of CD25 – Cells Into Stable T Regulatory Cells in Patients With Autoimmune Hepatitis显示文摘 | Maria Serena Longhi Rodrigo Liberal Beth Holder Simon C. Robson Yun Ma Giorgina Mieli–Vergani Diego Vergani | 2012 | Gastroenterology2012，，7： | 1 |
| 7 | Autoimmune hepatitis: A comprehensive review显示文摘 | Rodrigo Liberal Charlotte R. Grant Giorgina Mieli-Vergani Diego Vergani | 2012 | Journal of Autoimmunity2012，，： | 1 |
| 8 | HIPPOCRATES®project:A proof of concept of a collaborative program for hepatitis C virus micro-elimination in a prison setting显示文摘BACKGROUND In the last few years we have witnessed a revolution in the treatment of hepatitis C virus(HCV)infection.With the introduction of direct-acting antiviral agents(DAAs),sustained virological response(SVR)is achieved in more than 95%of the patients.The focus is now being turned to the global targets set by the World Health Organization,with the aim of achieving HCV elimination by 2030.Prison inmates constitute one of the high-risk groups,and receive treatment less frequently due to several barriers in access to health care.AIM To describe the management and follow-up of a cohort of HCV monoinfected patients treated with DAA in the prison setting,where tertial referral liver center specialists locally provide,on-site assessment and treatment for the prisoners.METHODS A prospective observational study was conducted from April 2017 to March 2020,which included all HCV monoinfected prison inmates in the largest Northern Portugal prison.Demographic,clinical,and laboratory data,as well as transient elastography measurements,were collected onsite by the medical team and prospectively recorded.Patients were treated with DAA according to international guidelines.The primary endpoint was SVR at post-treatment week 12.RESULTS There were 98 monoinfected HCV male inmates(mean age,42.7±8.6 years)included in the analysis.Injecting drugs or tattooing were reported in 74.5%,with 38.8%of the latter being done in prison.Alcohol consumption of more than 30 g/d was referred in 69.4%.The most prevalent genotype was 1a(54.1%),followed by 3(27.6%),4(9.2%)and 1b(6.1%).Pretreatment fibrosis degree was mild-tomoderate(F0-F2)in 77.6%and severe in 22.4%(F3-F4).Treatment regimens chosen were:45.9%elbasvir/grazoprevir,29.6%sofosbuvir/velpatasvir,and 12.2%sofosbuvir/ledispavir and glecaprevir/pibrentasvir.No major adverse events were observed.SVR at post-treatment week 12 was 99%.CONCLUSION In a population considered to be both hard-to-access and a cornerstone for HCV elimination,the onsite evaluation and treatment of HCV-infected prisoners,achieved an exceptional highly effective success rate.This type of collaborative program should be considered to be expanded,to support hepatitis C elimination efforts. | Rui Gaspar Rodrigo Liberal Jorge Tavares Rui Morgado Guilherme Macedo | 2020 | World Journal of Hepatology2020，12，12： | 1 |
| 9 | Pathogenesis of autoimmune hepatitis显示文摘 | Rodrigo Liberal Maria Serena Longhi Giorgina Mieli-Vergani Diego Vergani | 2011 | Best Practice & Research Clinical Gastroenterology2011，，6： | 1 |
| 10 | Autoimmune hepatitis: A comprehensive review显示文摘 | Rodrigo Liberal Charlotte R. Grant Giorgina Mieli-Vergani Diego Vergani | 2012 | Journal of Autoimmunity2012，，： | 1 |
| 11 | Autoimmune Hepatitis After Liver Transplantation显示文摘 | Rodrigo Liberal Maria Serena Longhi Charlotte R. Grant Giorgina Mieli–Vergani Diego Vergani | 2012 | Clinical Gastroenterology and Hepatology2012，，4： | 1 |
| 12 | “Porto-pulmonary hypertension: A comprehensive review”显示文摘 | Rodrigo Liberal Charlotte R. Grant Rui Baptista Guilherme Macedo | 2015 | Clinics and Research in Hepatology and Gastroente2015，，2： | 1 |
| 13 | Autoimmune hepatitis: A comprehensive review显示文摘 | Rodrigo Liberal Charlotte R. Grant Giorgina Mieli-Vergani Diego Vergani | 2012 | Journal of Autoimmunity2012，，： | 1 |
| 14 | Discontinuation of antiviral therapy in chronic hepatitis B patients显示文摘Nucleos(t)ide analogs(NUC)are the first-line therapy for patients with chronic hepatitis B(CHB)recommended by most current guidelines.NUC therapy decreases progression of liver disease,reduces the risk of liver-related complications,and improves the quality of life of patients with CHB.Although indefinite or long-term NUC therapy is usually recommended,this strategy raises several concerns,such as side-effects,adherence,costs,and patient willingness to stop therapy.Recent data showed the feasibility,efficacy,and safety of stopping antiviral therapy in carefully selected CHB patients,leading to its incorporation in international guidelines.Patients who discontinue NUC have a higher likelihood of hepatitis B surface antigen(HBsAg)loss compared to patients who continue on therapy.Recommendations pertaining endpoints allowing safety discontinuation of NUC therapy differ among international guidelines.For hepatitis B e antigen(HBeAg)-positive patients,durable HBeAg seroconversion is considered an acceptable treatment endpoint.For HBeAg-negative patients,some guidelines propose undetectability hepatitis B virus DNA for at least 2 or 3 years,while others consider HBsAg loss as the only acceptable endpoint.CHB patients who stop therapy should remain under strict clinical and laboratorial follow-up protocols to detect and manage relapses in a timely manner.No reliable predictor of relapse has been consistently identified to date,although quantitative HBsAg has been increasingly studied as a reliable biomarker to predict safe NUC discontinuation. | Renato Medas Rodrigo Liberal Guilherme Macedo | 2021 | World Journal of Clinical Cases2021，9，24： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员